Updates on our Coordinated Funding Mechanism

New ‘Global Research Improving Pandemic Preparedness’ (GRIPP) Group established to develop a GloPID-R Coordinated Funding Mechanism

 At the GloPID-R General Assembly in Sao Paulo (October 24-25, 2023), the membership endorsed a first coordinated research funding call. After agreeing the name, a key next step was to engage members by establishing the ‘Global Research Improving Pandemic Preparedness (GRIPP)’ Programme Group under the leadership of Dr Val Snewin of the UK Department of Health & Social Care (DHSC).

The GRIPP Programme Group has held regular meetings to take forward the themes agreed at the General Assembly:

  • Strengthening the clinical research ecosystem in low and middle-income countries
  • Improving collaborative surveillance research and risk prediction

Members agreed that aim of the GRIPP mechanism is to leverage the research investments already made by GloPID-R members in pandemic preparedness and clinical trials, to add value, and to create something ‘greater than the sum of its parts’.

The steps and structure of the future coordinated funding call will be informed by the Stakeholder Group which will involve researchers, policy makers and communities.

Programme development builds on the GloPID-R Funders Living Roadmap Principles. It has been informed by the Global Alliance for Chronic Diseases (GACD) Secretariat and supported by contributions from DLR in Germany.

The GloPID-R Secretariat will coordinate the call and is currently considering staff requirements. Next steps include providing an update to the new Board and discussion at an upcoming Members meeting.

Hans Hagen, GloPID-R Scientific and Advocacy Director, presented GloPID-R’s coordinated funding initiative when he delivered the keynote address at the ERA4Health workshop in Brussels, Belgium on February 8 – 9, 2024 (see related article in this Newsletter).


GloPID-R Funders Living Roadmap for Clinical Trial Coordination

EU Flag

The GloPID-R Secretariat is a project which receives funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101094188.